On July 24, 2019-Helix BioPharma Corp. (TSX: HBP), ("Helix" or the "Company"), an immunooncology company developing innovative drug candidates for the prevention and treatment of cancer, reported that it will be presenting at the RHK Capital 2019 Disruptive Growth & Healthcare Conference (www.disruptnyc.com).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RHK Capital’s Disruptive Growth & Healthcare Conference showcases life science companies that focus on solutions for unmet medical needs and growth companies with disruptive technologies and business models. The 2019 Disruptive Growth & Healthcare Conference will be held on Wednesday, September 4th and Thursday, September 5th in New York.

"We are pleased to present Helix at this venue," said Dr. Heman Chao, Helix’s Chief Executive Officer. "As part of the Company’s objective to increase awareness of the Company’s novel DOS47 tumor microenvironment platform, the Company will be actively participating in select conferences and non-deal roadshows during the second half of calendar 2019".